In vitro efficacy of high-dose tobramycin against burkholderia cepacia complex and stenotrophomonas maltophilia isolates from cystic fibrosis patients

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 1, 2015, Pages 711-713

  Ratjen, Anina ^a   Yau, Yvonne ^a   Wettlaufer, Jillian ^a   Matukas, Larissa ^b   Zlosnik, James E A ^c   Speert, David P ^c   LiPuma, John J ^d   Tullis, Elizabeth ^b   Waters, Valerie ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIUM ISOLATE; BIOFILM; BROTH DILUTION; BURKHOLDERIA CEPACIA COMPLEX; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PROSPECTIVE STUDY; PROTEIN SYNTHESIS; STENOTROPHOMONAS MALTOPHILIA; BURKHOLDERIA INFECTIONS; COMPLICATION; DRUG EFFECTS; GRAM-NEGATIVE BACTERIAL INFECTIONS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; BIOFILMS; BURKHOLDERIA CEPACIA COMPLEX; BURKHOLDERIA INFECTIONS; CYSTIC FIBROSIS; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; STENOTROPHOMONAS MALTOPHILIA; TOBRAMYCIN;

EID: 84920129629     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04123-14     Document Type: Article

References (23)

1. Alexander BD, Petzold EW, Reller LB, Palmer SM, Davis RD, Woods CW, Lipuma JJ. 2008. Survival after lung transplantation of cystic fibrosis patients infected with Burkholderia cepacia complex. Am J Transplant 8:1025-1030. http://dx.doi.org/10.1111/j.1600-6143.2008.02186.x.
2. Corey M, Farewell V. 1996. Determinants of mortality from cystic fibrosis in Canada, 1970-1989. Am J Epidemiol 143:1007-1017. http://dx.doi .org/10.1093/oxfordjournals.aje.a008664.
3. Tablan OC, Chorba TL, Schidlow DV, White JW, Hardy KA, Gilligan PH, Morgan WM, Carson LA, Martone WJ, Jason JM, Jarvis WR. 1985. Pseudomonas cepacia colonization in patients with cystic fibrosis: risk factors and clinical outcome. J Pediatr 107:382-387. http://dx.doi.org/10 .1016/S0022-3476(85)80511-4.
4. Waters V, Atenafu EG, Lu A, Yau Y, Tullis E, Ratjen F. 2013. Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients. J Cyst Fibros 12:482-486. http://dx.doi .org/10.1016/j.jcf.2012.12.006.
5. Waters V, Yau Y, Prasad S, Lu A, Atenafu E, Crandall I, Tom S, Tullis E, Ratjen F. 2011. Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease. Am J Respir Crit Care Med 183:635-640. http://dx.doi.org/10.1164/rccm.201009-1392OC.
6. Horsley A, Jones AM. 2012. Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation. Cochrane Database Syst Rev 10:CD009529. http://dx.doi.org/10 .1002/14651858.CD009529.pub2.
7. Horsley A, Webb K, Bright-Thomas R, Govan J, Jones A. 2011. Can early Burkholderia cepacia complex infection in cystic fibrosis be eradicated with antibiotic therapy? Front Cell Infect Microbiol 1:18. http://dx .doi.org/10.3389/fcimb.2011.00018
8. Gilchrist FJ, Webb AK, Bright-Thomas RJ, Jones AM. 2012. Successful treatment of cepacia syndrome with a combination of intravenous cyclosporin, antibiotics and oral corticosteroids. J Cyst Fibros 11:458-460. http://dx.doi.org/10.1016/j.jcf.2012.04.002.
9. Grimwood K, Kidd TJ, Tweed M. 2009. Successful treatment of cepacia syndrome. J Cyst Fibros 8:291-293. http://dx.doi.org/10.1016/j.jcf.2009 .04.002.
10. Andrade A, Valvano MA. 2014. A Burkholderia cenocepacia gene encoding a non-functional tyrosine phosphatase is required for the delayed maturation of the bacteria-containing vacuoles in macrophages. Microbiology 160:1332-1345. http://dx.doi.org/10.1099/mic.0.077206-0.
11. Nzula S, Vandamme P, Govan JR. 2002. Influence of taxonomic status on the in vitro antimicrobial susceptibility of the Burkholderia cepacia complex. J Antimicrob Chemother 50:265-269. http://dx.doi.org/10.1093 /jac/dkf137.
12. Waters V. 2012. New treatments for emerging cystic fibrosis pathogens other than Pseudomonas. Curr Pharm Des 18:696-725. http://dx.doi.org /10.2174/138161212799315939.
13. Konstan MW, Flume PA, Kappler M, Chiron R, Higgins M, Brockhaus F, Zhang J, Angyalosi G, He E, Geller DE. 2011. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J Cyst Fibros 10:54-61. http://dx.doi.org/10.1016/j.jcf .2010.10.003.
14. Buroni S, Pasca MR, Flannagan RS, Bazzini S, Milano A, Bertani I, Venturi V, Valvano MA, Riccardi G. 2009. Assessment of three resis-tance-nodulation-cell division drug efflux transporters of Burkholderia cenocepacia in intrinsic antibiotic resistance. BMC Microbiol 9:200. http: //dx.doi.org/10.1186/1471-2180-9-200.
15. Jassem AN, Zlosnik JE, Henry DA, Hancock RE, Ernst RK, Speert DP. 2011. In vitro susceptibility of Burkholderia vietnamiensis to aminoglycosides. Antimicrob Agents Chemother 55:2256-2264. http://dx.doi.org/10 .1128/AAC.01434-10.
16. Brooke JS. 2012. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev 25:2-41. http://dx.doi.org/10 .1128/CMR.00019-11.
17. nd informational supplement, M100-S22. Clinical and Laboratory Standards Institute, Wayne, PA.
18. Wu K, Yau YC, Matukas L, Waters V. 2013. Biofilm compared to conventional antimicrobial susceptibility for Stenotrophomonas maltophilia isolates from cystic fibrosis patients. Antimicrob Agents Chemother 57:1546-1548. http://dx.doi.org/10.1128/AAC.02215-12.
19. Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A. 1999. The Calgary biofilm device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 37:1771-1776.
20. Biddick R, Spilker T, Martin A, LiPuma JJ. 2003. Evidence of transmission of Burkholderia cepacia, Burkholderia multivorans and Burkholderia dolosa among persons with cystic fibrosis. FEMS Microbiol Lett 228:57-62. http://dx.doi.org/10.1016/S0378-1097(03)00724-9.
21. LiPuma JJ. 2001. Microbiological and immunologic considerations with aerosolized drug delivery. Chest 120:118S-123S. http://dx.doi.org/10 .1378/chest.120.3-suppl.118S
22. Bjarnsholt T, Ciofu O, Molin S, Givskov M, Hoiby N. 2013. Applying insights from biofilm biology to drug development-can a new approach be developed? Nat Rev Drug Discov 12:791-808. http://dx.doi.org/10 .1038/nrd4000.
23. Yu Q, Griffin EF, Moreau-Marquis S, Schwartzman JD, Stanton BA, O'Toole GA. 2012. In vitro evaluation of tobramycin and aztreonam versus Pseudomonas aeruginosa biofilms on cystic fibrosis-derived human airway epithelial cells. J Antimicrob Chemother 67:2673-2681. http://dx .doi.org/10.1093/jac/dks296.